Reference
Kwok WC, et al. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. Thoracic Cancer 13: 2057-2063, No. 14, Jul 2022. Available from: URL: http://doi.org/doi/10.1111/1759-7714.14528
Rights and permissions
About this article
Cite this article
Afatinib/gefitinib/osimertinib. Reactions Weekly 1924, 27 (2022). https://doi.org/10.1007/s40278-022-23380-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-23380-z